Search Results

The QuickVue® Semi-Q hCG-Combo is a one-step immunoassay intended for the semi-quantitative detection of human chorionic gonadotropin (hCG) in serum and the qualitative detection of hCG in urine for the early detection of pregnancy. The QuickVue Semi-Q hCG-Combo is intended for use by health care professionals.

The test is a rapid immunoassay for the semi-quantitative detection of hCG in serum and the qualitative detection of hCG in urine. This test is to be used for the early detection of pregnancy. Serum or urine is added to the Sample Well on the Test Cassette. Shortly after addition of the sample, a blue procedural Control Line will appear in the Result Window. If hCG is present in the sample, a pink-to-purple Test Line will also appear. If hCG is not present, only the blue procedural Control Line will appear. Serum results are interpreted by comparing the color development of the Test Line with a Reference Line. Serum results are reported as negative, positive less than 25 mIU/ml or positive greater than 25 mIU/mL. Urine results are interpreted as negative or positive.

Here's a breakdown of the acceptance criteria and study information for the QuickVue® Semi-Q hCG-Combo, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Sizes and Data Provenance

• Test Set Sample Size: Not explicitly stated as a single number for each study. However, the accuracy study used "serum and urine samples obtained from women presenting for pregnancy testing." The Physician's Office Laboratory (POL) study used an unspecified number of samples where "The results obtained at each site agreed 100% with the expected results."
• Data Provenance: The POL studies were conducted at "three geographically distinct sites in the United States." The provenance of the samples for the accuracy study is not specified beyond "women presenting for pregnancy testing." The studies are retrospective as they are comparing against an already existing predicate device.

3. Number of Experts and Qualifications for Ground Truth

• Number of Experts: Not explicitly stated for either the accuracy study or the POL study.
• Qualifications of Experts: For the POL studies, the users were "doctor's office personnel with diverse educational backgrounds and work experience." This implies typical healthcare professionals who would use such a test in a clinical setting, rather than specialized experts establishing a technical ground truth. For the predicate device (Hybritech® ICON® II HCG ImmunoConcentration™ Assay), the "ground truth" would be the result from that device, which is presumably established via its own validation.

4. Adjudication Method

• Adjudication Method: Not explicitly mentioned. In the context of a direct comparison to a predicate device, the predicate's result itself often serves as the reference, implying no separate adjudication process beyond the predicate's inherent result. For the POL studies, "expected results" were used, suggesting a pre-determined or known outcome for the samples, rather than a dynamic adjudication process by experts.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• MRMC Study: No, a multi-reader multi-case (MRMC) comparative effectiveness study was not conducted to assess how human readers improve with AI vs without AI assistance. This device is a rapid immunoassay, a diagnostic test where the output is directly interpreted (presence/absence of line for urine, comparison to reference line for serum), rather than an imaging or complex algorithm requiring human-in-the-loop assistance in the sense of AI.

6. Standalone Performance Study (Algorithm Only)

• Standalone Study: Yes, the studies described are essentially standalone performance studies of the device itself.
  • The "direct comparison of the test to the Hybritech® ICON® II HCG ImmunoConcentration™ Assay" demonstrates the device's performance (algorithm/system only) against a known standard.
  • The intra- and inter-assay precision, lot-to-lot consistency, and interference studies are all evaluations of the device's intrinsic standalone performance.

7. Type of Ground Truth Used

• Type of Ground Truth:
  • For the accuracy study, the ground truth was based on the results of a predicate device: the "Hybritech® ICON® II HCG ImmunoConcentration™ Assay for hCG detection."
  • For the Physician's Office Laboratory studies, the ground truth was "expected results," indicating that the samples used likely had known hCG statuses (e.g., positive or negative based on prior testing or clinical knowledge).

8. Sample Size for the Training Set

• Training Set Sample Size: Not specified. As this is a rapid immunoassay, the concept of a "training set" in the context of machine learning algorithms is not directly applicable in the same way. The development and optimization of such a test involve various R&D processes, but not typically a labeled "training set" for an AI algorithm.

9. How Ground Truth for the Training Set Was Established

• Ground Truth for Training Set: Not applicable in the context of an AI training set. For an immunoassay, the "ground truth" for development and optimization would stem from established biochemical principles, known concentrations of hCG, and comparisons to reference methods, ensuring the test reagents and design accurately detect hCG.

Ask a specific question about this device